In 2014, the Centers for Medicare & Medicaid Services waived patient cost sharing for anesthesia services during screening colonoscopies. 1 The current professional guidelines recommend that sedation be provided by the gastroenterologist-nurse team; a separate anesthesiologist or nurseanesthetist should be involved and paid separately only for patients with an increased risk of sedationrelated complications. 2 The stated rationale is that the provision of anesthesia has become standard practice for colonoscopies and that eliminating cost sharing may increase the rates of these examinations. We examined the costs and potential benefit of the Medicare rule change.
Methods | We quantified costs based on published articles regarding the volume of screening colonoscopy, 3 rate of anesthesia use, 1 proportion of services performed in low-risk patients, 4 and average costs per anesthesia service. 4 Using a scenario without the rule change as the comparison, we computed incremental anesthesia service costs to Medicare using the following 3 scenarios: maintaining the 2013 rate of anesthesia use, a 10% increase to that rate, and a 20% increase to that rate. This study was approved by the institutional review board of RAND Corporation. The benefit was calculated as cost per colorectal cancer prevented. We first estimated the association between anesthesia use and colonoscopy screening rates in 2008 for 143 metropolitan statistical areas. Rates of anesthesia use were derived from Medicare claims (detailed methods described elsewhere 4 ) and colonoscopy screening rates from Behavioral Risk Factor Surveillance System data for patients aged 65 to 75 years, defined as the proportion of eligible respondents with at least 1 screening colonoscopy in the past 10 years. The two rates were correlated using a linear regression. We then used published data for the association between the rate of colonoscopy screening and colorectal cancer incidence 5 to estimate additional screenings needed to prevent 1 case of colorectal cancer per 100 000 persons. Sensitivity analyses were conducted using the upper bound of the 95% CI of the estimated association between anesthesia use and colonoscopy screening (the lower bound is negative and does not generate a meaningful cost estimate) and assuming a 50% increase in the association between colonoscopy screening and colorectal cancer incidence, respectively.
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Invited Commentary page 1789 Table 1 shows the cost calculations. Compared with the scenario without the rule change, the incremental cost to Medicare would be $5.5 million per year based on the 2013 rate of anesthesia use of 50% 1 or $16.7 million if the rate increases to 70%. In all 3 scenarios, about two-thirds of the incremental costs to Medicare would be for low-risk patients. For every percentage-point increase in the rate of anesthesia use, we estimated a 0.03-percentage-point increase (95% CI, −0.01 to 0.07) in the rate of colonoscopy screening; each percentage-point increase in the rate of colonoscopy screening was associated with a 0.12-percentage-point decrease in the rate of colorectal cancer. 5 Using a 2012 colonoscopy screening rate of 73.9%
Results |
for patients who were 65 to 75 years old and a 2011 incidence of 151.3 cases per 100 000 people who were 65 to 75 years old, the incremental cost of anesthesia use per prevented incidence of cancer was $21.2 million for the 2013 rate of anesthesia use of 50%, $9.0 million using the upper bound of the 95% CI of the estimated association between anesthesia use and colonoscopy screening, and $14.1 million assuming a 50% increase in the association between colonoscopy screening and colorectal cancer incidence ( Table 2) .
Discussion | The results of our analysis cast doubt on the value associated with Medicare coverage of anesthesia services during screening colonoscopies for patients at low risk of sedationrelated complications. Although our study is limited by its cross-sectional nature, the central finding of high cost relative to benefits is robust for a range of assumptions. Our findings also raise questions about the role of the Centers for Medicare & Medicaid Services and other payers. Should payers promote evidence-based practices through their coverage decisions, or should they protect patients financially from prevailing practices even when such practices are not supported by current evidence?
A potential solution would be for payers to create payment bundles for endoscopy procedures that include anes- 
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Association Between Narrow Pharmacy Networks and Medication Adherence
In narrow or preferred pharmacy networks, in-network pharmacies negotiate reduced prescription prices with insurance plans. Plans then offer their members reduced cost sharing to incentivize in-network pharmacy use, thereby increasing the network's prescription volume. In 2014, 75% of Medicare Part D and 70% of exchange plan enrollees were in a narrow or preferred network drug plan. Narrow networks are common in commercial plans as well.
1 Concerns have been raised that these networks adversely affect medication adherence owing to reduced geographic access. 2, 3 Others argue that networks encourage members to establish a pharmacy home where pharmacists can better support adherence and coordinated care. 4 We assessed the effect of narrow network implementation on members' medication adherence. We also examined whether prepost adherence changes between plans that implemented narrow networks and those that did not were different in the following 2 subgroups: plans with and plans without 90-day prescription programs, which are known to boost adherence. Combined with narrow network implementation, these programs may be associated with synergistic improvements in medication adherence.
Methods | Eligible members were enrolled for all 12 months of 2012 and/or 2013 (January 1 through December 31, 2012, and/or January 1 through December 31, 2013) in commercial drug plans that implemented narrow networks in 2013 or 2014. Data analysis took place from January 1, 2012, through December 31, 2013. The network design provided minimal or no reimbursement for costs associated with prescriptions filled at out-of-network pharmacies. Members' deidentified data were used as permitted by the Health Insurance Portability and Accountability Act. Institutional review board approval was not needed for this study. Plans that implemented narrow networks in 2013 were considered intervention plans; those that implemented them in 2014 were considered control plans. For all plans, CVS/caremark was the pharmacy benefits manager. Using difference-in-difference analyses, controlling for the clustering of members in plans, we assessed the differences in members' medicationpossession ratio (MPR) before (2012) and after (2013) network implementation separately for statins, antihypertensive medications, oral antidiabetic medications, and antidepressant medications. The MPR was defined as the days' supply from the first through last times that the prescription was filled divided by the days between the first fill date and December 31 of that year. In an interaction analysis, we explored whether MPR differences before and after narrow network implementation between the intervention and control plans differed significantly between the following 2 subgroups: plans with 90-day prescription programs in place in both 2012 and 2013 and plans without these programs.
Results | Two narrow network plans (67 906 members) and 3 nonnetwork plans (149 989 members) were analyzed. 
